secwatch.observer — SEC 8-K summary
======================================

Issuer:     ADMA BIOLOGICS, INC. (ADMA)
CIK:        0001368514
Form:       8-K
Filed at:   2026-08-05T20:10:51+00:00
Accession:  0001140361-26-031423
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ADMA Q2 2026 net income $37.8M (+11% YoY); ASCENIV revenue $102.9M (+24% YoY)
-----------------------------------------------------------------------------

- Total revenue $124.4M (+2% YoY); GAAP net income $37.8M (+11% YoY); GAAP basic EPS $0.17 (+17% YoY).
- ASCENIV revenue $102.9M (+24% YoY); BIVIGAM revenue $19.4M (-49% YoY but sequential improvement from Q1 2026 trough).
- Gross margin expanded to 69% from 55% YoY, driven by product mix shift toward higher-margin ASCENIV and yield-enhanced manufacturing.
- Adjusted EBITDA $61.8M (+22% YoY); FY2026 guidance reiterated: revenue $530-560M, adj. EBITDA $265-300M.
- Repurchased ~7.1M shares in Q2 (13.8M YTD, 5.3% of shares outstanding); SG-001 development on track for pre-IND submission by year-end.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1368514/000114036126031423/0001140361-26-031423-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1368514/000114036126031423/ef20079311_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-26-031423

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer